Thank you, Sam. First, I would like to mention and remind all that much about the information we're discussing during this call is also included in press release issued earlier today and in our 10-K filed with the SEC. I encourage you to visit our website at lightpath.com on specifically the section titled “Investor Relations”. Now on to my remarks pertaining to the fourth quarter and year-end fiscal 2020. Sam's remark covered some of our financial performance along with key elements of our strategic direction. So I will be specifically discussing key financial areas. Revenue for the first quarter of fiscal 2020 was approximately $9.1 million, up from $8.7 million in both third quarter and fourth quarter 2019 -- third quarter 2020 sorry and fourth quarter 2019. For the year, revenues were $35 million, up from $33.7 million in fiscal 2019. IR product revenue was $4.8 million in Q4 2020 or 53% of total revenue, up from $4.3 million or 50% in the third quarter 2020 and $4.7 million, or 54% of the total and the prior period. Visual precision -- visible precision molded optics or PMO products revenue in fourth quarter 2020 was $3.9 million or 43% of the total same as third quarter 2020 or 44% of the total in third quarter 2020 and $3.5 million or 40% of the total in the fourth quarter 2019. For the year, IR product revenues were $18.1 million or 52% of the total of 5%, up 5% from about $17.2 million, or 51% of the total in the fiscal 2019. PMO revenues were $14.6 million or 42% of the total in fiscal 2020 and up 4% from about $14 million or 42% of the total prior year. Demands of our revenue for the fourth quarter and full year in respective periods were from speciality products, specialty products and non-recurring engineering products, which varied greatly from quarter-to-quarter, were substantially smaller contributors to the consolidated revenue. With respect to our margin profile, generally speaking, PMO products are small and almost entirely molded. So we have faster turnaround times, higher volume applications, and more automated processing. These products are also generally low in price. We historically have had margins averaging in the 40% to 50% range. This group represents about 42% of our total revenue in fiscal 2020. You can see that of the two primary segments, PMO is a small group with the higher margin. The IR product group represents a larger and faster growing market opportunity. IR margins have historically been in the 20% to 35% range with a new molded IR lenses which use our proprietary internally developed BD6 material on the top side is not able to go higher with efficiencies. As part of our gross margin improvement strategies, we have been aggressively working on marketing new products and targeting new customers using line of innovative BD6 while attempting to convert existing customers to the extent possible from using our germanium lenses to our BD6 lenses. Moving on, gross margin in the fourth quarter of fiscal 2020 was $3.5 million, an increase of 24% as compared to approximately $2.8 million in the same quarter of prior fiscal year. Total cost of sales was $5.6 million for the fourth quarter 2020 down from $5.9 million in the prior year. The lower total cost of sales is meaningful when you consider that the total sales increased 4%. Gross margin under the percentage of revenue was 39% for the fourth quarter 2020 as compared to 32% in the fourth quarter 2019. The increase in gross margin and now as a percentage of revenues is primarily driven by an increase in sales and an improved cost structure, along with elimination of elevated costs, including labor, manufacturing, in efficiencies, and increased overhead expenses associated with the relocation of our New York facility in the prior year period. For the year, gross margin for fiscal 2020 was $13.8 million, an increase of 11% from $12.5 million in fiscal 2019. The total cost to sales was approximately $21.1 million in fiscal 2020, slightly lower than $21.2 million in the prior year. Gross Margin as a percentage of revenue was 40% for the 2020 compared to 37% for fiscal 2019. The increase in gross margin reflects the changes to our cost structure, as well as improvements made in the second, third and fourth quarters of fiscal 2020 after several factors negatively impacted the first quarter of fiscal 2020. As in the fiscal third quarter, demand in aggregate have been strong. Although there are pockets of weakness that emerges followed from COVID-19, which includes, as Sam mentioned, the delivery and processing challenges. We continue to enjoy strong demand from secular or long term market applications including 5G. For this product, we believe, we could have had large order flow if we had not been capacity constrained. Additional capacity has been added, and we're accelerating certain build-ups. Our production volumes are growing. In the fourth quarter 2020, we produced 1.2 million lenses up from 904,000 lenses in Q3 of 2020, 868,000 lenses made in second quarter 2020. Unit volume sold in the fourth quarter of 2020 was up 62% as compared to the fourth quarter of fiscal 2019 and up 41% year-on-year. The total units sold in 2013 was $3.6 million, up from $2.6 million last year. During the fourth quarter of fiscal 2020, total operating expenses was approximately $2.9 million, a decrease of $1 million, or nearly 26% as compared to $3.9 million in the same period of the prior fiscal year. The largest reduction came from SG&A which decreased from about 900,000 and new product developments which decreased by about 117,000. The change from the prior year reflects the elimination of non-recurring expenses from last year, which are related to the relocation of the New York facility, as well as other reduced personnel and overhead costs from synergies, and to a lesser extent limited travel and marketing expenses from COVID-19 restrictions. The product development expense variation reflects shifting and personnel of the newly created product management function, which is also in our selling, general and administrative expenses. For the full year, total operating expenses in 2020 was $11.7 million, down $2 million or about 15% from $13.7 million in 2019. SG&A was down $1.5 million and product development were down 300,000 for reasons similar to the changes in the fourth quarter. It should also be noted that expenses in the third quarter was reduced by gains on disposal of equipment of approximately 136,000, which is masking some of the savings when compared to total 2020 expenses. Our consolidated corporate income tax in the U.S. is shielded by our net operating loss carry forward benefits of approximately $74 million at June 30, 2020. But we do have to pay income tax to the countries of certain foreign subsidiaries. Income tax expense for the fourth quarter of fiscal 2019 included the reversal of 406,000 of income tax benefits recorded in the first half of fiscal 2019 due to the change in company's estimated utilization of U.S. net operating loss carry forward benefits for 2019. During the fourth quarter of fiscal 2020, the company recorded income tax expense of 90,000 as compared to 496,000 in the same period of the prior fiscal year. During the fiscal 2020, the company recorded income tax expenses of $764,000, primarily related to the income tax from operations in China and Chinese withholding tax associated with the intercompany dividend. With higher revenues, strong margin, management of expenses and lower income tax, net income for the fourth quarter of fiscal 2020 was $657,000 compared to a net loss of $1.8 million for the fourth quarter of fiscal 2019, which was negatively impacted by elevated costs, including labor costs, manufacturing inefficiencies, and increased overhead expenses associated with the relocation of the company's New York facilities. We’re operating far more efficiently and profitably having completed that transition, improve our cost structure and increased revenue margins. Net income for the year was $867,000, up from a net loss of $2.7 million. Moving to the balance sheet and cash flow related items, capital expenditures, including equipment financed through leases was $938,000 in the fourth quarter 2020 and $2.4 million for the year, up from $326,000 and $2.5 million respectively in the prior periods. Given that we have been running at near capacity, we intend to continue to invest similarly in 2021. Meanwhile, net cash provided by operation was $3.7 million for fiscal 2020, up from $411,000 in prior year, with fourth quarter 2020 contributing $1.8 million or about 49% of full year amounts. Total debt, including finance leases was reduced by approximately $650,000 or 10% in fiscal 2020 from June 30 2019. While cash balance June 30 2020, was $5.4 million, up from $4.6 million at June 30 2019. As of June 30 2020, LightPaths 12-month backlog was $19.1 million, an increase of 11% from $17.1 million as of June 30 2019. It should be noted that this is natural for -- that it is natural for backlog to fluctuate during the year as a result of the timing of such bookings of large orders and annual renewals. The company has also undisclosed backlog of beyond 12 months. On a final note, through the increase of our share price and market value, we're pleased to have been added to the resell of microcap index effect with the annual reconstitution on June 29 2020. With this review of our financial highlights and recent developments concluded, I will turn the call over to the operator so that we may begin with question and answer session.